E Fund Management Co., Ltd. Spring Works Therapeutics, Inc. Transaction History

E Fund Management Co., Ltd.

$1.93 Billion
Q3 2024

A detailed history of E Fund Management Co., Ltd. transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, E Fund Management Co., Ltd. holds 8,873 shares of SWTX stock, worth $332,205. This represents 0.01% of its overall portfolio holdings.

Number of Shares

8,873

Previous 9,467 6.27%

Holding current value

$332,205

Previous $356,000 20.22%

% of portfolio

0.01%

Previous 0.02%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$32.04 - $42.76 $19,031 - $25,399	-594 Reduced 6.27%	8,873 $284,000
Q2 2024 Aug 12, 2024	BUY	$36.06 - $47.62 $35,374 - $46,715	981 Added 11.56%	9,467 $356,000
Q1 2024 May 13, 2024	BUY	$36.5 - $52.5 $26,791 - $38,535	734 Added 9.47%	8,486 $417,000
Q4 2023 Feb 06, 2024	SELL	$18.94 - $37.24 $27,917 - $54,891	-1,474 Reduced 15.98%	7,752 $282,000
Q3 2023 Nov 13, 2023	SELL	$23.12 - $31.38 $86,098 - $116,859	-3,724 Reduced 28.76%	9,226 $213,000
Q2 2023 Aug 11, 2023	BUY	$23.15 - $32.71 $12,223 - $17,270	528 Added 4.25%	12,950 $340,000
Q1 2023 May 11, 2023	SELL	$24.97 - $34.05 $106,946 - $145,836	-4,283 Reduced 25.64%	12,422 $320,000
Q4 2022 Feb 14, 2023	SELL	$21.73 - $28.72 $2,129 - $2,814	-98 Reduced 0.58%	16,705 $434,000
Q3 2022 Nov 14, 2022	SELL	$24.1 - $39.66 $77,794 - $128,022	-3,228 Reduced 16.12%	16,803 $479,000
Q2 2022 Aug 15, 2022	BUY	$18.36 - $60.07 $284,102 - $929,523	15,474 Added 339.57%	20,031 $493,000
Q1 2022 May 12, 2022	BUY	$48.97 - $65.46 $136,675 - $182,698	2,791 Added 158.04%	4,557 $257,000
Q1 2021 May 12, 2021	BUY	$65.1 - $93.59 $114,966 - $165,279	1,766 New	1,766 $129,000

Others Institutions Holding SWTX

# of Institutions

238

Shares Held

69.8M

Call Options Held

144K

Put Options Held

257K

View Full List

About SpringWorks Therapeutics, Inc.

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $2.34B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

More about SWTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on E Fund Management Co., Ltd. with notifications on news.

Account

E Fund Management Co., Ltd. Spring Works Therapeutics, Inc. Transaction History